Showing results (151-160 of 162) with videos related to

Sort By:
Pageof 17
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|February 12, 2015
Dacomitinib (PF-00299804), a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor, demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitroLiancheng Zhu, Salvatore Lopez, Stefania Bellone, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 31, 2017
Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results from the COMPASS TrialKyaw L Aung, Sandra E Fischer, Robert E Denroche, et al.
Gynecologic Oncology Reports|November 18, 2020
Prescribed medical cannabis in women with gynecologic malignancies: A single-institution survey-based studyEmily M Webster, Ghanshyam S Yadav, Stefan Gysler, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 26, 2015
Analysis of 13 cell types reveals evidence for the expression of numerous novel primate- and tissue-specific microRNAsEric Londin, Phillipe Loher, Aristeidis G Telonis, et al.
British Journal of Cancer|June 29, 2016
Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivoEmiliano Cocco, Salvatore Lopez, Jonathan Black, et al.
Nature Cancer|May 25, 2026
Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomized, multiarm, run-in phase trialKimberly J Perez, Andressa Dias Costa, Alexander Jordan, et al.
Genome Biology|May 25, 2017
N-BLR, a primate-specific non-coding transcript leads to colorectal cancer invasion and migrationIsidore Rigoutsos, Sang Kil Lee, Su Youn Nam, et al.
Molecular Cancer Therapeutics|June 4, 2016
SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu ExpressionJonathan Black, Gulden Menderes, Stefania Bellone, et al.
Gynecologic Oncology|November 30, 2016
Polymerase ε (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitroStefania Bellone, Eliana Bignotti, Silvia Lonardi, et al.
Scientific Reports|July 4, 2025
Pan-cancer immune and stromal deconvolution predicts clinical outcomes and mutation profilesBhavneet Bhinder, Verena Friedl, Sunantha Sethuraman, et al.
Pageof 17